COVID-19 & Cancer

According to data from the American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry, black or African-American patients with cancer and COVID-19 were more likely than non-Hispanic white patients to experience delays or disruptions in cancer treatment during the pandemic.

Patients with cancer and immunoglobulin deficiency have compromised immune systems–based response to COVID-19 vaccines.

According to data from a European registry, approximately 1 in 6 patients with cancer who recovered from COVID-19 infection experienced long-term sequelae (ie, “long-haul” COVID-19), placing them at increased risk for death or discontinuation of anticancer treatment.

The ongoing COVID-19 pandemic has brought to the forefront the importance of advance care planning.

Patients with cancer have been prioritized in vaccination programs due to the increased likelihood of poor clinical outcomes from a SARS-CoV-2 infection.